Saxagliptin: a New DPP-4 inhibitor for the treatment of type 2 diabetes mellitus

Author： Tahrani Abd Piya Milan Barnett Anthony

ISSN： 0741-238X

Source： Advances in Therapy, Vol.26, Iss.7, 2009-07, pp. : 736-736

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes

By Pratley Richard E. Salsali Afshin

Current Medical Research and Opinion, Vol. 23, Iss. 4, 2007-04 ,pp. : 919-931

Informa Healthcare

Access to resources Recommend Favorite

Saxagliptin for the treatment of type 2 diabetes mellitus: Focus on recent studies

By Schwartz Sherwyn L.

Annals of Medicine, Vol. 44, Iss. 2, 2012-03 ,pp. : 157-169

Informa Healthcare

Access to resources Recommend Favorite

Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials

By Karasik Avraham Aschner Pablo Katzeff Harvey Davies Michael J. Stein Peter P.

Current Medical Research and Opinion, Vol. 24, Iss. 2, 2008-02 ,pp. : 489-496

Informa Healthcare

Access to resources Recommend Favorite

Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes

By Rosenstock J. Aguilar-Salinas C. Klein E. Nepal S. List J. Chen R.

Current Medical Research and Opinion, Vol. 25, Iss. 10, 2009-10 ,pp. : 2401-2411

Informa Healthcare

Access to resources Recommend Favorite

Effectiveness and safety of glimepiride and iDPP4, associated with metformin in second line pharmacotherapy of type 2 diabetes mellitus: systematic review and meta‐analysis

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (ELECTRONIC), Vol. 69, Iss. 3, 2015-03 ,pp. : 292-304

John Wiley & Sons Inc

Access to resources Recommend Favorite